Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 15/20 | 0.69 |
| ▸ | FLT3 | P36888 | 4/20 | 0.69 |
| ▸ | FLT1 | P17948 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.69 |
| ▸ | STK3 | Q13188 | 2/20 | 0.69 |
| ▸ | FLT4 | P35916 | 2/20 | 0.69 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.69 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.69 |
| ▸ | STK4 | Q13043 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830178 | 1.00 | KDR (0.69) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL5830274 | 0.91 | KDR (0.56) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL5830271 | 0.91 | KDR (0.56) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL1395114 | 0.86 | FGFR1 (0.53) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL4781166 | 0.86 | FGFR1 (0.53) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL4410662 | 0.85 | KDR (0.74) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL4410660 | 0.85 | KDR (0.74) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL5830528 | 0.84 | FGFR1 (0.49) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL5830603 | 0.84 | FGFR1 (0.49) | KDRFGFR1PDGFRBFLT3FLT1 | |
| SCHEMBL5829865 | 0.84 | ALK (0.54) | KDRFGFR1PDGFRBFLT3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | KDR 4431/4885FGFR1 4574/4885PDGFRB 3497/4885 |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | KDR 1114/4885FGFR1 785/4885PDGFRB 1332/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | KDR 1114/4885FGFR1 785/4885PDGFRB 1332/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | KDR 4776/4885FGFR1 4449/4885PDGFRB 2778/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KDR 4866/4885FGFR1 4760/4885PDGFRB 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.